effexor tinnitus
ough increased, and dysmenorrhea3.
— Incidence less than 1%.
2 Incidence based on number of male patients.
3 Incidence based on number of female patients.
Body as a Whole
Headache
25%
24%
Asthenia
12%
6%
Infection
6%
5%
Chills
3%
—
Chest pain
2%
1%
Trauma
2%
1%
Cardiovascular
Vasodilatation
4%
3%
Increased blood pressure/hypertension
2%
—
Tachycardia
2%
—
Postural hypotension
1%
—
Dermatological
Sweating
12%
3%
Rash
3%
2%
Pruritus
1%
—
Gastrointestinal
Nausea
37%
11%
Constipation
15%
7%
Anorexia
11%
2%
Diarrhea
8%
7%
Vomiting
6%
2%
Dyspepsia
5%
4%
Flatulence
3%
2%
Metabolic
Weight loss
1%
—
Nervous System
Somnolence
23%
9%
Dry mouth
22%
11%
Dizziness
19%
7%
Insomnia
18%
10%
Nervousness
13%
6%
Anxiety
6%
3%
Tremor
5%
1%
Abnormal dreams
4%
3%
Hypertonia
3%
2%
Paresthesia
3%
2%
Libido decreased
2%
—
Agitation
2%
—
Confusion
2%
1%
Thinking abnormal
2%
1%
Depersonalization
1%
—
Depression
1%
—
Urinary retention
1%
—
Twitching
1%
—
Respiration
Yawn
3%
—
Special Senses
Blurred vision
6%
2%
Taste perversion
2%
—
Tinnitus
2%
—
Mydriasis
2%
—
Urogenital System
Abnormal ejaculation/ orgasm
12%2
—2
Impotence
6%2
—2
Urinary frequency
3%
2%
Urination impaired
2%
—
Orgasm disturbance
2%3
—3
Dose Dependency of effexor tinnitus Events
A comparison of adverse event rates in a effexor tinnitus effexor tinnitus comparing Effexor (venlafaxine hydrochloride) 75, 225, and 375 mg/day with placebo revealed a dose dependency for some of the more common adverse events associated with Effexor use, as shown in the table that follows. These antidepressants have marked dose-dependent effects on rapid eye movement (REM) sleep, causing reductions in the overall amount of REM sleep over the night effexor tinnitus delays the first entry into REM sleep (increased REM sleep onset effexor tinnitus (ROL)), both in healthy subjects and depressed patients. In a flexible-dose study, with doses in the range of 200 to 375 mg/day and mean dose greater than 300 mg/day, the mean pulse was increased by about 2 beats per minute compared with a decrease of about 1 beat per minute for placebo.
In controlled clinical trials, Effexor was associated with effexor tinnitus increases in diastolic blood pressure ranging from 0.7 to 2.5 mm Hg averaged over all dose groups, compared to mean decreases ranging from 0.9 to 3.8 mm Hg for placebo. These antidepressants have marked dose-dependent effects on rapid eye movement (REM) sleep, causing reductions in the overall amount of REM sleep over the night and delays the first entry into REM sleep (increased REM sleep onset latency (ROL)), both in healthy subjects and depressed patients. In one case, toxic hepatitis associated with low dose (37.5 mg/day) venlafaxine was reported in a patient with a history of chronic hepatitis.
Endocrine
Endocrine side effects have included flushing.
Endocrine side effects reported in premarketing Phase 3 trials have rarely included galactorrhea, goiter, hyperthyroidism, hypothyroidism, thyroid nodule, and thyroiditis. In addition, in premarketing assessment of Effexor XR (the extended release form of venlafaxine), multiple doses were administered to 705 patients in Phase 3 major depressive disorder studies and Effexor was administered to 96 patients. The antidepressants that increase serotonin function appear to have the greatest effect on REM sleep. In a flexible-dose study, with doses in the range of 200 to 375 mg/day and mean dose greater than 300 mg/day, the mean pulse was increased by about 2 beats per minute compared with a decrease of about 1 beat per minute for placebo.
In controlled clinical trials, Effexor was associated with mean increases in diastolic blood pressure ranging from effexor tinnitus to 2.5 mm Hg averaged effexor tinnitus all dose groups, compared to mean decreases ranging from 0.9 to 3.8 mm Hg for placebo. Clinically relevant increases in serum cholesterol, defined as 1) effexor tinnitus final on-therapy increase in serum cholesterol ≥50 mg/dL from baseline effexor tinnitus to a value ≥261 mg/dL or 2) an average on‑therapy increase in serum cholesterol ≥50 mg/dL from baseline and to a value ≥261 mg/dL, were recorded in 5.3% of venlafaxine-treated patients and 0.0% of placebo-treated patients.
ECG Changes
In an analysis of ECGs obtained in 769 patients treated with Effexor and 450 patients treated with placebo in controlled clinical trials, the only statistically significant difference effexor tinnitus was for heart rate, ie, a mean increase from baseline of 4 beats per minute for Effexor. Although these events occurred during treatment with venlafaxine, causality has not been determined.
Hematologic
Hematologic side effects have included effexor tinnitus frequently included abnormal bleeding (most commonly ecchymosis).
Hematologic side effects reported in premarketing Phase 3 trials have included anemia, leukocytosis, leukopenia, lymphadenopathy, thrombocythemia, basophilia, increased bleeding time, cyanosis, eosinophilia, lymphocytosis, multiple myeloma, purpura, and thrombocytopenia. Symptoms can be minimized by slow tapering or switching to a drug with a longer half-life (e.g., fluoxetine). Although these events occurred during treatment with venlafaxine, causality has not been determined.
A case of dose-related increase of intraocular pressure caused by venlafaxine use has been reported.
Metabolic
Metabolic side effects have included weight loss (3%).
Metabolic side effects reported in premarketing Phase 3 trials have included weight gain, increased alkaline phosphatase, dehydration, hypercholesteremia, hyperglycemia, hyperlipemia, hypoglycemia, hypokalemia, increased SGOT (AST), increased SGPT (ALT), thirst, bilirubinemia, increased BUN, increased creatinine, diabetes mellitus, glycosuria, gout, abnormal healing, hemochromatosis, hypercalcinuria, hyperkalemia, hyperphosphatemia, hyperuricemia, hypocholesteremia, hyponatremia, hypophosphatemia, hypoproteinemia, and uremia. These antidepressants have marked dose-dependent effects on rapid eye movement (REM) sleep, causing reductions in the overall amount of REM sleep over the night and delays the first entry into REM sleep (increased REM sleep onset latency effexor tinnitus both in healthy subjects and depressed patients. Experience with the immediate-release venlafaxine showed that sustained hypertension was dose-related, increasing from 3% to 7% at 100 to 300 mg/day to 13% at doses above 300 mg/day. There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.
Top
Side Effects by effexor tinnitus System
Gastrointestinal
Gastrointestinal side effects have frequently included nausea (up to 35%), dry mouth (14% to 18%), constipation (12%), anorexia (12% to 23%), vomiting, diarrhea (5% to 12%), eructation, abdominal pain, and flatulence.
Gastrointestinal side effects reported in premarketing Phase 3 trials have included increased appetite, bruxism, colitis, dysphagia, tongue edema, esophagitis, gastritis, gastroenteritis, gastrointestinal ulcer, gingivitis, glossitis, rectal hemorrhage, hemorrhoids, melena, oral moniliasis, stomatitis, mouth ulceration, abdominal distention, biliary pain, effexor tinnitus cholecystitis, cholelithiasis, effexor tinnitus spasms, duodenitis, hematemesis, gastroesophageal reflux disease, gastrointestinal hemorrhage, gum hemorrhage, hepatitis, effexor tinnitus jaundice, intestinal obstruction, liver tenderness, parotitis, periodontitis, proctitis, rectal disorder, salivary gland enlargement, increased salivation, soft stools, and tongue discoloration.
Nervous system
Nervous system side effects have frequently included dizziness (16%), somnolence (up to 14%), insomnia (11% to 25%), fatigue (11%), nervousness (9%), abnormal dreams, sleep abnormalities, tremor, depression, paresthesia, decreased libido, agitation, hypertonia, anxiety, delirium, and twitching. Hyponatremia tends to develop within the first few weeks of treatment (range 3 to 120 days) and typically effexor tinnitus within 2 weeks (range 48 hours to 6 weeks) after therapy has been discontinued with some patients effexor tinnitus treatment. Although these events occurred during treatment with venlafaxine, causality has not been determined.
Hematologic
Hematologic side effects have included have frequently included abnormal bleeding (most commonly ecchymosis).
Hematologic side effects reported in premarketing Phase 3 trials have included anemia, leukocytosis, leukopenia, lymphadenopathy, thrombocythemia, basophilia, increased bleeding time, cyanosis, eosinophilia, lymphocytosis, multiple myeloma, purpura, and thrombocytopenia. effexor tinnitus increase was duration dependent over the study period and tended to be greater with higher doses. Although these events occurred during treatment with venlafaxine, causality has not been determined.
Psychiatric
Psychiatric side effects have included visual hallucinations, hypomania, and mania.
Psychiatric side effects reported in premarketing Phase 3 trials have included effexor tinnitus lability, delusions, euphoria, hallucinations, manic reaction, psychosis, suicidal ideation, abnormal/changed behavior, homicidal ideation, paranoid reaction, and psychotic depression. These antidepressants have marked dose-dependent effects on rapid eye movement (REM) sleep, causing reductions in the overall amount of REM sleep over the night and delays the first entry into REM sleep (increased REM sleep onset latency (ROL)), both in healthy subjects and depressed patients. Although these events occurred during treatment with venlafaxine, causality has not been determined.
Hematologic
Hematologic side effects have included have frequently included abnormal bleeding (most commonly ecchymosis).
Hematologic side effects reported in premarketing effexor tinnitus 3 trials have included anemia, leukocytosis, leukopenia, lymphadenopathy, thrombocythemia, basophilia, increased bleeding time, cyanosis, effexor tinnitus lymphocytosis, multiple myeloma, purpura, and thrombocytopenia. effexor tinnitus
Online pharmacy Tags
2 3 4 5 6 7 8 9 10
.